OverviewSuggest Edit

OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.

The company believes that better and earlier detection of cancer through liquid biopsies will:


  • Improve patient outcomes
  • Increase the life expectancy of cancer patients
  • Significantly reduce health care costs

Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.

These invasive tests are expensive, time-consuming when time may be of utmost importance, and lead to both patient anxiety and physician uncertainty about the diagnosis.

Our next generation liquid biopsy diagnostics will use blood or urine samples to detect the presence or absence of cancer. These diagnostics are:

  • Simple
  • Accurate
  • Fast
  • Non-invasive

OncoCyte’s initial focus is on cancers with large patient populations and significant unmet need.

TypePublic
HQAlameda, US
Websiteoncocyte.com

Latest Updates

Employees (est.) (Feb 2019)16
Share Price (Mar 2019)$3.6 (-2%)

Key People/Management at OncoCyte

William Annett

William Annett

President & Chief Executive Officer
Lyssa Friedman

Lyssa Friedman

Vice President, Clinical and Regulatory Affairs
Lyndal Hesterberg

Lyndal Hesterberg

Senior Vice President, Research & Development
Mitch Levine

Mitch Levine

CFO
Kristine C. Mechem

Kristine C. Mechem

Vice President, Marketing & Planning
William Seltzer

William Seltzer

Vice President, Clinical Services
Show more

OncoCyte Office Locations

OncoCyte has an office in Alameda
Alameda, US (HQ)
1010 Atlantic Ave #102
Show all (1)
Report incorrect company information

OncoCyte Financials and Metrics

OncoCyte Revenue

USD

Net income (Q2, 2018)

(8.3m)

EBIT (Q2, 2018)

(8.1m)

Market capitalization (21-Mar-2019)

188.7m

Closing stock price (21-Mar-2019)

3.6

Cash (30-Jun-2018)

10.3m
OncoCyte's current market capitalization is $188.7 m.
Annual
USDFY, 2016FY, 2017

Sales and marketing expense

2.4m

General and administrative expense

5.5m9.2m

R&D expense

5.7m7.2m

Operating expense total

11.1m18.8m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Sales and marketing expense

655.0k477.0k710.0k658.0k1.2m

General and administrative expense

1.2m1.3m1.2m2.0m1.1m4.3m1.8m3.1m

R&D expense

1.7m1.2m1.4m1.8m2.0m1.8m1.5m3.8m

Operating expense total

2.9m(2.5m)(2.6m)4.5m(3.6m)(6.8m)3.9m8.1m
Annual
USDFY, 2016FY, 2017

Cash

10.2m7.6m

Accounts Receivable

14.3m

Inventories

285.0k

Current Assets

12.7m8.5m
Quarterly
USDQ1, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

5.9m12.7m11.4m8.6m11.0m12.6m10.3m

Inventories

457.0k

Current Assets

7.9m15.3m13.5m10.3m12.5m14.1m11.4m

PP&E

615.0k
Annual
USDFY, 2016FY, 2017

Net Income

(11.2m)(19.4m)

Depreciation and Amortization

145.0k338.0k

Inventories

101.0k

Accounts Payable

(48.0k)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.9m)(2.5m)(2.6m)(4.7m)

Accounts Payable

403.0k192.0k870.0k211.0k
USDY, 2018

Financial Leverage

1.8 x
Show all financial metrics

OncoCyte Operating Metrics

FY, 2016

Patents Issued

1

Patents and Patent Applications

13
Show all operating metrics
Report incorrect company information

OncoCyte Online and Social Media Presence

Embed Graph
Report incorrect company information

OncoCyte News and Updates

OncoCyte Corporation to Present at Cowen and Company 39th Annual Health Care Conference in Boston

ALAMEDA, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, CEO of OncoCyte Corporation, will be presenting at the Cowen and Company 39th Annual Healt…

Thinking about buying stock in Aurora Cannabis Inc., Advanced Micro Devices, Biotime Inc., Oncocyte Corp. or PG&E Corp.?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AMD, BTX, OCX, and PCG. NEW YORK, Jan. 30, 2019 To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

OncoCyte upgraded to buy at Janney on high hopes for lung cancer biopsy test

Shares of OncoCyte Corp. soared more than 200% on Tuesday after the developer of cancer detection tests reported positive results from a trial of a new biopsy test of lung cancer. Janney analyst Paul Knight upgraded the stock to buy and raised his fair-value target to $8, or 37% above its current t…

OncoCyte Schedules Announcement and Conference Call to Discuss Results from Key R&D Validation Study of DetermaVu™

Conference call scheduled for Tuesday, January 29, 2019 at 8:30am ET Conference call scheduled for Tuesday, January 29, 2019 at 8:30am ET

OncoCyte Provides Progress Update on Ongoing Studies

Results of Key R&D Validation Study expected in January Results of Key R&D Validation Study expected in January
Show more
Report incorrect company information

OncoCyte Frequently Asked Questions

  • Who are OncoCyte key executives?

    OncoCyte's key executives are William Annett, Lyssa Friedman and Lyndal Hesterberg.

  • How many employees does OncoCyte have?

    OncoCyte has 16 employees.

  • Who are OncoCyte competitors?

    Competitors of OncoCyte include Thriva, hVIVO and Immucor.

  • Where is OncoCyte headquarters?

    OncoCyte headquarters is located at 1010 Atlantic Ave #102, Alameda.

  • Where are OncoCyte offices?

    OncoCyte has an office in Alameda.

  • How many offices does OncoCyte have?

    OncoCyte has 1 office.